TrialCurveVebreltinib in PTPRZ1-MET fusion glioma: reconstructed Kaplan–Meier curves
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Commun (Lond). 2026 Mar 11;46:0019. doi: 10.34133/cancomm.0019 |
|---|---|
| DOI | 10.34133/cancomm.0019 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Full analysis set (n = 81)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Vebreltinib group 6.3 months; Control group 3.4 months. Survival at 12 months: Vebreltinib group 30%; Control group 20%. Hazard ratio Vebreltinib group vs Control group 0.54 (95% CI 0.34–0.87).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Vebreltinib group | 42 | 33 | 6.3 |
| Control group | 39 | 37 | 3.4 |
- Vebreltinib group vs Control group: reconstructed HR 0.54 (95% CI 0.34–0.87)
Landmark survival (reconstructed)
| Time | Vebreltinib group | Control group |
|---|---|---|
| 6 mo | 52.5% | 30.8% |
| 12 mo | 30.0% | 19.9% |
| 18 mo | 26.6% | 8.5% |
| 24 mo | 16.6% | 8.5% |
| 36 mo | 11.1% | 2.8% |
Checks against the published figure
- Vebreltinib group median: printed 6.3, reconstructed 6.28 pass
- Control group median: printed 3.4, reconstructed 3.36 pass
- Vebreltinib group events: printed 33, reconstructed 33 pass
- Vebreltinib group n: printed 42, reconstructed 42 pass
- Control group events: printed 37, reconstructed 37 pass
- Control group n: printed 39, reconstructed 39 pass
- hazard ratio: printed 0.52, reconstructed 0.542 pass
Progression-free survival — Full analysis set (n = 81)
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Vebreltinib group 1.9 months; Control group 1.1 months. Survival at 12 months: Vebreltinib group 9%. Hazard ratio Vebreltinib group vs Control group 0.59 (95% CI 0.36–0.97).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Vebreltinib group | 42 | 37 | 1.9 |
| Control group | 39 | 32 | 1.1 |
- Vebreltinib group vs Control group: reconstructed HR 0.59 (95% CI 0.36–0.97)
Landmark survival (reconstructed)
| Time | Vebreltinib group | Control group |
|---|---|---|
| 6 mo | 18.2% | 12.8% |
| 12 mo | 9.1% | — |
| 18 mo | 6.1% | — |
| 24 mo | 3.0% | — |
Checks against the published figure
- Vebreltinib group median: printed 1.9, reconstructed 1.87 pass
- Control group median: printed 1.1, reconstructed 1.06 pass
- Vebreltinib group events: printed 37, reconstructed 37 pass
- Vebreltinib group n: printed 42, reconstructed 42 pass
- Control group events: printed 32, reconstructed 32 pass
- Control group n: printed 39, reconstructed 39 pass
- hazard ratio: printed 0.54, reconstructed 0.593 pass
Overall survival — Patients with a maximum lesion diameter at baseline of ≤3.0 cm
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Vebreltinib group 32.5 months; Control group 4.2 months. Survival at 12 months: Vebreltinib group 60%; Control group 22%. Hazard ratio Vebreltinib group vs Control group 0.25 (95% CI 0.07–0.93).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Vebreltinib group | 8 | 4 | 32.5 |
| Control group | 9 | 9 | 4.2 |
- Vebreltinib group vs Control group: reconstructed HR 0.25 (95% CI 0.07–0.93)
Landmark survival (reconstructed)
| Time | Vebreltinib group | Control group |
|---|---|---|
| 6 mo | 87.5% | 44.4% |
| 12 mo | 60.0% | 22.2% |
| 18 mo | 60.0% | — |
| 24 mo | 60.0% | — |
Checks against the published figure
- Vebreltinib group median: printed 32.5, reconstructed 32.5 pass
- Control group median: printed 4.2, reconstructed 4.21 pass
- Vebreltinib group events: printed 4, reconstructed 4 pass
- Vebreltinib group n: printed 8, reconstructed 8 pass
- Control group events: printed 9, reconstructed 9 pass
- Control group n: printed 9, reconstructed 9 pass
- hazard ratio: printed 0.27, reconstructed 0.248 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials